The BCR-ABL1 fusion gene [2], the alleged driver of the malignant phenotype in these leukemias, is known to activate several lines of downstream signaling including the MAP kinase, mTOR, JAK-STAT, and JAK-MYC pathways [3]. This evidence concerns the gene ABL1 and leukemia.